Clinical Trial

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Study acronym: NEOSTART
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-08
Trial Details
NCT Number NCT06673693
Lead Sponsor Sun Yat-sen University
Conditions Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
Enrollment 24 participants
Start Date 2025-06-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07